Last reviewed · How we verify
NCT06277024
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
NA trial testing Combination of Cardonizumab with Lenvatinib and SOX regimen in Overall Response Rate in 50 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Combination of Cardonizumab with Lenvatinib and SOX regimen — full drug profile →
Conditions studied
- Overall Response Rate — all drugs for Overall Response Rate →
Sponsor
Fujian Medical University
Who can join
Adults 18 to 75, any sex, with Overall Response Rate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06277024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overall Response Rate
Currently open trials in the same condition.
- NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
- NCT06531681 — Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac) · recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06277024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 26 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06277024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing